The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia

被引:71
|
作者
Zalewska-Szewczyk, Beata
Andrzejewski, Witalij
Mlynarski, Wojciech
Jedrychowska-Danska, Krystyna
Witas, Henryk
Bodalski, Jerzy
机构
[1] Med Univ Lodz, Oncohematol Unit, Dept Pediat, PL-91738 Lodz, Poland
[2] Med Univ Lodz, Dept Biol Mol, Lodz, Poland
关键词
L-asparaginase; antibodies; allergy; acute lymphoblastic leukemia; children;
D O I
10.1080/10428190701292049
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The primary aim of the study was to evaluate the importance of anti-asparaginase antibodies for L-asparaginase activity in children with standard and medium risk acute lymphoblastic leukemia ( ALL). Forty-seven children with newly diagnosed ALL were included into the prospective study. Enzyme activity and the presence of anti-asparaginase antibodies ( IgG and IgM class) were determined. Anti-asparaginase antibodies were identified in 13/47 ( IgM class) and 10/ 47 ( IgG class) patients in the induction and in 19/47 ( IgM class) and 20/47 ( IgG class) patients in the reinduction phase of treatment. The enzyme activity was lower in patients that were positive for anti-asparaginase antibodies, especially in reinduction phase ( median 37 ( 20-180) vs 355 ( 141-499), p = 0.001). An association between anti-asparaginase antibodies and the allergic reaction to the drug was found. Besides, the children who developed anti-asparaginase antibodies in the induction phase of treatment showed lower event-free survival as well as overall survival in comparison with children without antibodies. Since our study was carried out in a small number of patients, this observation is only speculative and needs to be confirmed by a further study on a larger sample size, with multivariable analysis. However, our data suggest that L-asparaginase activity together with anti-asparaginase antibodies measurements may become useful for effective therapy of ALL.
引用
收藏
页码:931 / 936
页数:6
相关论文
共 50 条
  • [31] Down's syndrome in childhood acute lymphoblastic leukemia:: clinical characteristics and treatment outcome in four consecutive BFM trials
    Dördelmann, M
    Schrappe, M
    Reiter, A
    Zimmermann, M
    Graf, N
    Schott, G
    Lampert, F
    Harbott, J
    Niemeyer, C
    Ritter, J
    Dörffel, W
    Nessler, G
    Kühl, J
    Riehm, H
    LEUKEMIA, 1998, 12 (05) : 645 - 651
  • [32] The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia
    Wojtuszkiewicz, Anna
    Assaraf, Yehuda G.
    Hoekstra, Mirthe
    Sciarrillo, Rocco
    Jansen, Gerrit
    Peters, Godefridus J.
    Pieters, Rob
    Sonneveld, Edwin
    Escherich, Gabriele
    Kaspers, Gertjan J. L.
    Cloos, Jacqueline
    HAEMATOLOGICA, 2016, 101 (07) : 291 - 294
  • [33] Homozygous deletion of p16 gene in childhood acute lymphoblastic leukemia clinical outcome and prognostic significance.
    Barrette, S
    Murthy, SK
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 220 - 220
  • [34] CD10 AND CD34 EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN MOROCCO: Clinical Relevance and Outcome
    Dakka, Nadia
    Bellaoui, Hicham
    Bouzid, Nadia
    Khattab, Mohammed
    Bakri, Youssef
    Benjouad, Abdelaziz
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2009, 26 (04) : 216 - 231
  • [35] Impact of Clinical Hypersensitivity and Asparaginase Antibodies on Asparaginase Drug Activity in Egyptian Pediatric Acute Lymphoblastic Leukemia Patients
    Hassan, S.
    Hassanein, H.
    Sayed, S.
    Adwan, H.
    Sidhom, I.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S140 - S141
  • [36] Antibodies against 9-O-acetylated sialoglycans:: a potent marker to monitor clinical status in childhood acute lymphoblastic leukemia
    Pal, S
    Bandyopadhyay, S
    Chatterjee, M
    Bhattacharya, DK
    Minto, L
    Hall, AG
    Mandal, C
    CLINICAL BIOCHEMISTRY, 2004, 37 (05) : 395 - 403
  • [37] Promoter methylation and expression of SOCS3 affect the clinical outcome of pediatric acute lymphoblastic leukemia by JAK/STAT pathway
    Liu Kangkang
    Wu Zhengyu
    Chu Jinhua
    Yang Linhai
    Wang Ningling
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 115
  • [38] L-asparaginase activity and anti-L-asparaginase antibody as biomarkers in estimating PEG-asp-related anaphylaxis risk in childhood acute lymphoblastic leukemia patients
    Cui, Jiali
    Jiang, Lian
    Xu, Bei
    Bai, Yajie
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2023, 51 (03) : 28 - 35
  • [39] Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia - Correlation of expression and clinical outcome at first disease recurrence
    Wu, SL
    Gessner, R
    von Stackelberg, A
    Kirchner, R
    Henze, G
    Seeger, K
    CANCER, 2005, 103 (05) : 1054 - 1063
  • [40] Myeloid Antigen Expression in Childhood Acute Lymphoblastic Leukemia and Its Relevance for Clinical Outcome in Indonesian ALL-2006 Protocol
    Supriyadi, Eddy
    Veerman, Anjo J. P.
    Sutaryo
    Purwanto, Ignatius
    vd Ven, Peter M.
    Cloos, Jacqueline
    JOURNAL OF ONCOLOGY, 2012, 2012